
Validea's guru fundamental report indicates that UnitedHealth Group (UNH) scores 77% using its Growth Investor model, based on Martin Zweig's strategy, placing it just below the 80% threshold for 'some interest.' While UNH passes criteria such as P/E ratio, current quarter earnings, sales growth, and long-term EPS growth, it notably fails on revenue growth in relation to EPS growth and the consistency of earnings growth over the past several quarters. This presents a nuanced profile for growth investors, highlighting strong individual metrics alongside areas lacking persistent acceleration.
UnitedHealth Group (UNH) presents a nuanced profile for growth investors, scoring 77% on Validea's Martin Zweig-based model, which is just below the 80% threshold that typically indicates interest. The analysis reveals a company with several fundamental strengths, passing key tests for its P/E ratio, current quarter earnings, sales growth rate, long-term EPS growth, and insider transactions. However, the model flags critical weaknesses that temper the otherwise bullish indicators. Specifically, UNH fails on the metric comparing revenue growth to EPS growth, suggesting that earnings quality or margins may be driving performance more than top-line expansion. Furthermore, the model indicates a lack of persistent acceleration, with the company failing criteria for consistent earnings growth over the past several quarters and for current EPS growth exceeding its historical rate. This mixed assessment signifies that while UNH is a high-quality firm with positive current momentum, its growth pattern does not meet the strict criteria for sustained acceleration that the Zweig strategy prioritizes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment